Investors sentiment increased to 1.54 in Q3 2019. Its up 0.02, from 1.52 in 2019Q2. It is positive, as 10 investors sold DRNA shares while 25 reduced holdings. 29 funds opened positions while 25 raised stakes. 45.79 million shares or 1.41% more from 45.15 million shares in 2019Q2 were reported. Artal Group Inc has 1.00 million shares. Ra Capital Mgmt Limited Partnership, Massachusetts-based fund reported 2.46 million shares. Credit Suisse Ag owns 28,667 shares for 0% of their portfolio. 4,450 are owned by Ameritas Investment Prns. Alliancebernstein LP holds 65,600 shares or 0% of its portfolio. Bvf Inc Il has invested 1.85% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Next Gp reported 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Schroder Mgmt Group reported 107,734 shares. 34,693 were accumulated by Art Advisors Limited Liability Corporation. Sg Americas Secs has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 11,396 shares. Nuveen Asset Management Ltd reported 0% stake. Sio Cap Ltd Com has invested 1.71% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Tower Rech Capital Ltd Co (Trc) reported 400 shares. 73,246 were accumulated by Rafferty Asset Mngmt Ltd Llc. Aqr Cap Limited holds 0% or 17,707 shares in its portfolio.
Since November 19, 2019, it had 0 insider purchases, and 1 insider sale for $38.55 million activity.
Sphera Funds Management Ltd increased its stake in Dicerna Pharmaceuticals Inc (DRNA) by 79.57% based on its latest 2019Q3 regulatory filing with the SEC. Sphera Funds Management Ltd bought 250,358 shares as the company’s stock rose 89.40% . The institutional investor held 565,000 shares of the health care company at the end of 2019Q3, valued at $8.11M, up from 314,642 at the end of the previous reported quarter. Sphera Funds Management Ltd who had been investing in Dicerna Pharmaceuticals Inc for a number of months, seems to be bullish on the $1.83B market cap company. The stock increased 0.22% or $0.06 during the last trading session, reaching $26.79. About 703,625 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 90.76% since December 15, 2018 and is uptrending. It has outperformed by 90.76% the S&P500.
Sphera Funds Management Ltd, which manages about $647.32M US Long portfolio, decreased its stake in Amazon Com Inc (NASDAQ:AMZN) by 2,000 shares to 2,200 shares, valued at $3.82 million in 2019Q3, according to the filing. It also reduced its holding in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 171,087 shares in the quarter, leaving it with 165,713 shares, and cut its stake in Reata Pharmaceuticals Inc.
More notable recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were published by: Benzinga.com which released: “10 Biggest Price Target Changes For Monday – Benzinga” on November 25, 2019, also Nasdaq.com with their article: “KRTX Makes Giant Leap, The Medicines’ Working Well, AGRX On The Move – Nasdaq” published on November 19, 2019, Nasdaq.com published: “BUZZ-U.S. STOCKS ON THE MOVE-Kohl’s, Home Depot, JinkoSolar – Nasdaq” on November 19, 2019. More interesting news about Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) were released by: Nasdaq.com and their article: “BUZZ-U.S. STOCKS ON THE MOVE-Retail stocks, CRISPR Therapeutics, Slack Technologies – Nasdaq” published on November 19, 2019 as well as Finance.Yahoo.com‘s news article titled: “The Daily Biotech Pulse: Roche’s Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug – Yahoo Finance” with publication date: December 04, 2019.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage
Among 4 analysts covering Dicerna Pharma (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Dicerna Pharma has $5000 highest and $20 lowest target. $31’s average target is 15.71% above currents $26.79 stock price. Dicerna Pharma had 8 analyst reports since June 24, 2019 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Tuesday, November 19 with “Buy”. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Chardan Capital Markets on Friday, November 1. Robert W. Baird maintained it with “Outperform” rating and $5000 target in Monday, November 25 report. H.C. Wainwright maintained the shares of DRNA in report on Monday, June 24 with “Buy” rating. H.C. Wainwright maintained it with “Buy” rating and $22 target in Friday, November 1 report. The firm earned “Buy” rating on Monday, November 18 by SunTrust.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.